• 1
    Yarden Y, Baselga J, Miles D. Molecular approach to breast cancer treatment. Semin Oncol 2004; 31: 613.
  • 2
    Longley D, Harkin DP, Johnston PG. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3: 33038.
  • 3
    Parker W, Cheng Y. Metabolism and mechanism of action of 5-fluorouracil. Pharmacol Ther 1990; 48: 38195.
  • 4
    Houghton JA, Harwood FG, Tillman DM. Thymineless death in colon carcinoma cells is mediated via Fas signaling. PNAS 1997; 94: 814449.
  • 5
    Zhang W, Ramdas L, Shen W, Song S, Hu L, Hamilton S. Apoptotic response to 5-fluorouracil treatment is mediated by reduced polyamines, non-autocrine Fas ligand and induced tumor necrosis factor receptor 2. Cancer Biol Ther 2003; 2: 57278.
  • 6
    O'Connor P, Jackman J, Bae I, Myers T, Fan S, Mutoh M, Scudiero D, Monks A, Sausville E, Weinstein J, Friend S, Fornace AJ, et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 1997; 57: 4285300.
  • 7
    Lowe S, Bodis S, McClatchey A, Remington L, Ruley H, Fisher D, Housman D, Jacks T. p53 status and the efficacy of cancer therapy in vivo. Science 1994; 266: 80710.
  • 8
    Petak I, Tillman DM, Houghton JA. p53 dependence of Fas induction and acute apoptosis in response to 5-fluorouracil-leucovorin in human colon carcinoma cell lines. Clin Cancer Res 2000; 6: 443241.
  • 9
    Hwang P, Bunz F, Yu J, Rago C, Chan T, Murphy M, Kelso G, Smith R, Kinzler K, Vogelstein B. Ferredoxin reductase affects p53-dependent, 5-fluorouracil-induced apoptosis in colorectal cancer cells. Nat Med 2001; 7: 11117.
  • 10
    Adlard JW, Richman SD, Seymour MT, Quirke P. Prediction of the response of colorectal cancer to systemic therapy. Lancet Oncol 2002; 3: 7582.
  • 11
    Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34: 127481.
  • 12
    Peters G, Lankelma J, Kok R, Noordhuis P, van Groeningen C, van der Wilt C, Meyer S, Pinedo H. Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumors as compared with plasma. Cancer Chemother Pharmacol 1993; 31: 26976.
  • 13
    Schuller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, Utoh M, Mori K, Weidekamm E, Reigner B. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000; 45: 2917.
  • 14
    Carmichael J, DeGraff W, Gazdar A, Minna J, Mitchell J. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987; 47: 93642.
  • 15
    Moreno-Bueno G, Sanchez-Estevez C, Cassia R, Rodriguez-Perales S, Diaz-Uriarte R, Dominguez O, Hardisson D, Andujar M, Prat J, Matias-Guiu X, Cigudosa JC, Palacios J. Differential gene expression profile in endometrioid and nonendometrioid endometrial carcinoma: STK15 is frequently overexpressed and amplified in nonendometrioid carcinomas. Cancer Res 2003; 63: 5697702.
  • 16
    Tracey L, Villuendas R, Ortiz P, Dopazo A, Spiteri I, Lombardia L, Rodriguez-Peralto JL, Fernandez-Herrera J, Hernandez A, Fraga J, Dominguez O, Herrero J, et al. Identification of genes involved in resistance to interferon-{α} in cutaneous T-cell lymphoma. Am J Pathol 2002; 161: 182537.
  • 17
    Ballestar E, Ropero S, Alaminos M, Armstrong J, Setien F, Agrelo R, Fraga MF, Herranz M, Avila S, Pineda M, Monros E, Esteller M. The impact of MECP2 mutations in the expression patterns of Rett syndrome patients. Hum Genet 2005; 116: 91104.
  • 18
    Wingender E, Chen X, Hehl R, Karas H, Liebich I, Matys V, Meinhardt T, Pruss M, Reuter I, Schacherer F. TRANSFAC: an integrated system for gene expression regulation. Nucl Acids Res 2000; 28: 31619.
  • 19
    Grandori C, Wu K-J, Fernandez P, Ngouenet C, Grim J, Clurman BE, Moser MJ, Oshima J, Russell DW, Swisshelm K, Frank S, Amati B, et al. Werner syndrome protein limits MYC-induced cellular senescence. Genes Dev 2003; 17: 156974.
  • 20
    Tarsounas M, Munoz P, Claas A, Smiraldo PG, Pittman DL, Blasco MA, West SC. Telomere maintenance requires the RAD51D recombination/repair protein. Cell 2004; 117: 33747.
  • 21
    von Kobbe C, May A, Grandori C, Bohr VA. Werner syndrome cells escape hydrogen peroxide-induced cell proliferation arrest. FASEB J 2004; 18: 19702.
  • 22
    Mirjolet J, Didelot C, Barberi-Heyob M, Merlin J. G(1)/S but not G(0)/G(1)cell fraction is related to 5-fluorouracil cytotoxicity. Cytometry 2002; 48: 613.
  • 23
    Janicke RU, Sprengart ML, Wati MR, Porter AG. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 1998; 273: 935760.
  • 24
    Seoane J, Le H-V, Massague J. Myc suppression of the p21Cip1 Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 2002; 419: 72934.
  • 25
    Wu S, Cetinkaya C, Munoz-Alonso M, von der Lehr N, Bahram F, Beuger V, Eilers M, Leon J, LG L. Myc represses differentiation-induced p21CIP1 expression via Miz-1-dependent interaction with the p21 core promoter. Oncogene 2003; 22: 35160.
  • 26
    Ballestar E, Esteller M. The impact of chromatin in human cancer: linking DNA methylation to gene silencing. Carcinogenesis 2002; 23: 110309.
  • 27
    Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW, Vogelstein B. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 1999; 104: 26369.
  • 28
    Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 95767.
  • 29
    Mirjolet J, Barberi-Heyob M, Didelot C, Peyrat J, Abecassis J, Millon R, Merlin J. Bcl-2/Bax protein ratio predicts 5-fluorouracil sensitivity independently of p53 status. Br J Cancer 2000; 83: 13806.
  • 30
    Yoshikawa R, Kusunoki M, Yanagi H, Noda M, Furuyama JI, Yamamura T, Hashimoto-Tamaoki T. Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy. Cancer Res 2001; 61: 102937.
  • 31
    Ho JSL, Ma W, Mao DYL, Benchimol S. p53-dependent transcriptional repression of c-myc is required for G1 cell cycle arrest. Mol Cell Biol 2005; 25: 742331.
  • 32
    Ren B, Cam H, Takahashi Y, Volkert T, Terragni J, Young RA, Dynlacht BD. E2F integrates cell cycle progression with DNA repair, replication, and G2/M checkpoints. Genes Dev 2002; 16: 24556.
  • 33
    Hallstrom TC, Nevins JR. Specificity in the activation and control of transcription factor E2F-dependent apoptosis. PNAS 2003; 100: 1084853.
  • 34
    Wu X, Levine A. p53 and E2F-1 cooperate to mediate apoptosis. PNAS 1994; 91: 360206.
  • 35
    Kowalik T, DeGregori J, Schwarz J, Nevins J. E2F1 overexpression in quiescent fibroblasts leads to induction of cellular DNA synthesis and apoptosis. J Virol 1995; 69: 2491500.
  • 36
    Maxwell PJ, Longley DB, Latif T, Boyer J, Allen W, Lynch M, McDermott U, Harkin DP, Allegra CJ, Johnston PG. Identification of 5-fluorouracil-inducible target genes using cDNA microarray profiling. Cancer Res 2003; 63: 46026.
  • 37
    Norton J. ID helix-loop-helix proteins in cell growth, differentiation and tumorigenesis. J Cell Sci 2000; 113: 3897905.
  • 38
    Longley DB, Boyer J, Allen WL, Latif T, Ferguson PR, Maxwell PJ, McDermott U, Lynch M, Harkin DP, Johnston PG. The role of thymidylate synthase induction in modulating p53-regulated gene expression in response to 5-fluorouracil and antifolates. Cancer Res 2002; 62: 264449.
  • 39
    Troester MA, Hoadley KA, Sorlie T, Herbert B-S, Borresen-Dale A-L, Lonning PE, Shay JW, Kaufmann WK, Perou CM. Cell-type-specific responses to chemotherapeutics in breast cancer. Cancer Res 2004; 64: 421826.